Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Fyarro

Sirolimus

RLDNDA 213312 Aadi
Approved
Nov 22, 2021
Strengths
1
Listed patents
7

What does the FDA Orange Book show for Fyarro?

Fyarro contains Sirolimus and is the new drug FDA Orange Book record for NDA 213312. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 213312

New drug application identity from the Orange Book snapshot.

Application holder
Aadi Biosciences Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
7

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
1

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001100MG/VIALPOWDERINTRAVENOUSPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Aadi Biosciences Inc

The Orange Book identifies this organization as the applicant responsible for NDA 213312.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

7 listed patent expirations and 1 exclusivity date remain on or after Jul 26, 2026

The latest future date recorded across those files is Oct 28, 2040. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

11 other ANDAs and 3 other NDAs found

10 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 213312 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Powder · Intravenous

Sirolimus

1 application
Product rows
1
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-213312

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

NDA 213312
RLDRS
Strength
100MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    4 yr 9 mo ago

  2. Today

  3. Exclusivity ends · ODE-386

    Orphan-drug exclusivity (7 years)

    in 2 yr 4 mo

  4. Patent 8911786 expires

    Listed drug product patent expiration.

    in 2 yr 7 mo

  5. Patent 10206887 expires

    Listed drug product patent expiration.

    in 3 yr 9 mo

  6. Patent 10705070 expires

    Listed drug product patent expiration.

    in 9 yr 9 mo

  7. Patent 12061183 expires

    Listed drug product patent expiration.

    in 9 yr 9 mo

  8. Patent 10973806 expires

    Listed method-of-use patent (U-3258) expiration.

    in 10 yr 1 mo

  9. Patent 12133844 expires

    Listed method-of-use patent (U-4040) expiration.

    in 10 yr 1 mo

  10. Patent 12133844 expires

    Listed method-of-use patent (U-4041) expiration.

    in 10 yr 1 mo

  11. Patent 12133844 expires

    Listed method-of-use patent (U-4042) expiration.

    in 10 yr 1 mo

  12. Patent 11497737 expires

    Listed drug product patent expiration.

    in 14 yr 6 mo

Patent & exclusivity timeline

Protection horizon
20262028203020322034203620382040TodayExclusivity ODE-386: 2028-11-22Exclusivity ODE-386Patent 8911786: 2029-02-14Patent 8911786Patent 10206887: 2030-04-15Patent 10206887Patent 10705070: 2036-03-05Patent 10705070Patent 12061183: 2036-03-05Patent 12061183Patent 10973806: 2036-06-29Patent 10973806Patent 12133844: 2036-06-29Patent 12133844Patent 12133844: 2036-06-29Patent 12133844Patent 12133844: 2036-06-29Patent 12133844Patent 11497737: 2040-10-28Patent 11497737
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

SIROLIMUS

Strength

100MG/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 213312

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Marketing exclusivity

Hatch-Waxman
  • ODE-386Orphan-drug exclusivity (7 years)

    in 2 yr 4 mo

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8911786in 2 yr 7 mo
ProductU-3259
10206887in 3 yr 9 mo
Product
10705070in 9 yr 9 mo
Product
12061183in 9 yr 9 mo
Product
10973806in 10 yr 1 mo
U-3258
12133844in 10 yr 1 mo
U-4040
12133844in 10 yr 1 mo
U-4041
12133844in 10 yr 1 mo
U-4042
11497737in 14 yr 6 mo
Product

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Sirolimus family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Fyarro: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 213312 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo